Previous 10 |
home / stock / clvlf / clvlf news
Editor's note: Seeking Alpha is proud to welcome Alexander Schiller as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » Clinuvel Pharm...
I published my last valuation of Clinuvel Pharmaceuticals (OTCPK:CLVLY) on Seeking Alpha in January 2017 with a fair value of 20-27 USD/share. A lot of things have been happening in these two and a half years, so it's time to update my view - this time supported by a Monte Carlo simulation t...
Clinuvel ( CLVLY ) is a small biotech company which focuses on bringing the first-in-class drug for the treatment of EPP (Erythropoietic Protoporphyria) to the US market. The drug - SCENESSE - has already got approval from the EMA, while the FDA has rescheduled the PDUFA date to October 6, 2...
News, Short Squeeze, Breakout and More Instantly...
Clinuvel Pharms Ord Company Name:
CLVLF Stock Symbol:
OTCMKTS Market:
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE ® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company ...
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California’s most prolific investors and philanthropists at the Malibu home of Lady Gaga and Michael Polansky. The event, hosted by Lady Gaga and M...
UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level 1: CLVLY) today launched CYACÊLLE, a next generation of polychromatic solar care...